Introducing Imprivata Confirm ID: A New Product for Solving a Critical Workflow Challenge

Nick Castellano
Feb 09, 2015

 

Today, we launched Imprivata Confirm ID™, the industry’s first comprehensive product to enable a major shift from paper to electronic prescribing of controlled substances (EPCS).

EPCS can play an important role in addressing a national public health crisis—prescription drug abuse. More Americans die each year from overdoses on prescription medication than do from overdoses on heroin and cocaine combined.

EPCS can help address the problem by keeping a provider’s signature and DEA number safe, which reduces the possibility of fraud and drug diversion. The medication is tracked from the time it is prescribed to the moment the patient picks it up at the pharmacy.

But why did Imprivata, the healthcare IT security company, bring Imprivata Confirm ID to market? How does it fit with the existing portfolio of Imprivata products?

Like Imprivata OneSign® and Imprivata Cortext®, Imprivata Confirm ID is designed to improve provider productivity for better focus on patient care.  With the volume of prescriptions for controlled substances on the rise, EPCS can improve efficiency for providers by eliminating dual prescribing workflows (e-prescribing for non-controlled substances; printed prescriptions for controlled substances). However, the DEA interim final rule allowing EPCS stipulates a number of requirements that must be met.

Imprivata Confirm ID is the first product that offers provider identity-proofing, supervised enrollment of providers’ approved credentials, support for multiple DEA-approved two-factor authentication modalities for prescription signing, and comprehensive auditing and reporting tools. This eases adoption of the regulatory requirements for EPCS.

Imprivata Confirm ID also integrates directly into the e-prescribing workflows of leading EHRs, which simplifies EPCS for providers by enabling a single, consistent e-prescribing experience for all medications. Support for fingerprint biometric identification and one-time-password tokens also gives providers the necessary flexibility to leverage the two-factor authentication options that meet all their prescribing workflow requirements.

This increases efficiency and provider satisfaction while maintaining security, which is one of the core value propositions Imprivata offers across all our solutions. Our solutions, Imprivata Confirm ID included, allow providers to spend less time dealing with technology and more time focusing on their patients. 

If you are interested in learning more about Imprivata Confirm ID and the DEA requirements for EPCS, Imprivata will host a webinar titled “Introducing Imprivata Confirm ID: Fast, Secure Signing for e-Prescribing of Controlled Substances” on Tuesday, February 17, 2015 at 2 p.m. EST. To register, please visit: http://pages.imprivata.com/0215-Introducing-Imprivata-ConfirmID_LP-Register.html

Tags: